http://pharmalicensing.com/rss/ Latest market and business intelligence from the leading publishers worldwide. en-us http://pharmalicensing.com/rss/ http://pharmalicensing.com/images/pharmalicensing_logo.gif 144 Reykjavik, ICELAND, October 3, 2008 - deCODE genetics (Nasdaq:DCGN) today announced the filing of an investigational new drug (IND) application for DG071, the company's novel small-molecule modulator... http://pharmalicensing.com/redirs/news_rss//public/news/view/444638/6/decode-files-ind-for-dg071-a-novel-pde4-modulator-being-developed-for-alzheimers-and-other-cognitive-disorders http://pharmalicensing.com/redirs/news_rss//public/news/view/444638/6/decode-files-ind-for-dg071-a-novel-pde4-modulator-being-developed-for-alzheimers-and-other-cognitive-disorders Amsterdam, The Netherlands - 3 October, 2008 - Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it intends to incorporate additional... http://pharmalicensing.com/redirs/news_rss//public/news/view/444688/6/amt-intends-to-incorporate-additional-data-to-its-marketing-authorization-dossier-for-glybera http://pharmalicensing.com/redirs/news_rss//public/news/view/444688/6/amt-intends-to-incorporate-additional-data-to-its-marketing-authorization-dossier-for-glybera REDMOND, WASH. - October 3, 2008- Physio-Control, Inc., a wholly owned subsidiary of Medtronic, Inc., (NYSE: MDT) announced today that it has received clearance by the U.S. Food and Drug... http://pharmalicensing.com/redirs/news_rss//public/news/view/444704/6/physio-control-receives-fda-510-k-clearance-for-lifepak-20e-defibrillator-monitor http://pharmalicensing.com/redirs/news_rss//public/news/view/444704/6/physio-control-receives-fda-510-k-clearance-for-lifepak-20e-defibrillator-monitor DUBLIN, Ohio, Oct. 2, 2008 -- Cardinal Health, a global provider of products and services that improve the safety and productivity of health care, today announced agreements with the U.S. Drug... http://pharmalicensing.com/redirs/news_rss//public/news/view/444663/6/cardinal-health-resolves-controlled-substance-license-suspension http://pharmalicensing.com/redirs/news_rss//public/news/view/444663/6/cardinal-health-resolves-controlled-substance-license-suspension October 01, 2008-Pharmaceutical company Pharmaxis (ASX:PXS, NASDAQ:PXSL) today announced that a marketing application for the mucus clearing agent, Bronchitol, has been submitted to the Therapeutic... http://pharmalicensing.com/redirs/news_rss//public/news/view/444727/6/pharmaxis-files-first-marketing-application-for-bronchitol-in-australia http://pharmalicensing.com/redirs/news_rss//public/news/view/444727/6/pharmaxis-files-first-marketing-application-for-bronchitol-in-australia Paris (France), 30 September 2008 - Ipsen (Euronext; IPN) today announced that the U.S. Food and Drug Administration (FDA) provided notification that the Prescription Drug User Fee Act (PDUFA) action... http://pharmalicensing.com/redirs/news_rss//public/news/view/443565/6/fdas-first-cycle-review-of-dysport-to-be-completed-by-year-end-us-launch-of-dysport-on-track http://pharmalicensing.com/redirs/news_rss//public/news/view/443565/6/fdas-first-cycle-review-of-dysport-to-be-completed-by-year-end-us-launch-of-dysport-on-track September 30, 2008 Sydney, Australia--Biotechnology company Arana Therapeutics Limited (ASX: AAH) today announced it has submitted an Investigational New Drug application (IND) to the FDA (U.S. Food... http://pharmalicensing.com/redirs/news_rss//public/news/view/443668/6/arana-files-ind-for-lead-anti-inflammatory-product-art621 http://pharmalicensing.com/redirs/news_rss//public/news/view/443668/6/arana-files-ind-for-lead-anti-inflammatory-product-art621 Osaka, Japan, September 29, 2008-Takeda Pharmaceutical Company Limited ("Takeda") announced today that it filed a New Drug Application to the Ministry of Health, Labour and Welfare for Alogliptin... http://pharmalicensing.com/redirs/news_rss//public/news/view/443552/6/takeda-submitted-a-new-drug-application-for-alogliptin-in-japan-for-treatment-of-type-2-diabetes http://pharmalicensing.com/redirs/news_rss//public/news/view/443552/6/takeda-submitted-a-new-drug-application-for-alogliptin-in-japan-for-treatment-of-type-2-diabetes Osaka, Japan, September 29, 2008 ---Takeda Pharmaceutical Company Limited ("Takeda") announced today that it submitted a new drug application to the Ministry of Health, Labour and Welfare for Actos http://pharmalicensing.com/redirs/news_rss//public/news/view/443554/6/takeda-submitted-a-new-drug-application-in-japan-for-actos-orally-disintegrating-tablets http://pharmalicensing.com/redirs/news_rss//public/news/view/443554/6/takeda-submitted-a-new-drug-application-in-japan-for-actos-orally-disintegrating-tablets September 29, 2008 -- A U.S. Food and Drug Administration's analysis provides new evidence that the use of statins does not increase incidence of amyotrophic lateral sclerosis (ALS), a... http://pharmalicensing.com/redirs/news_rss//public/news/view/443591/6/fda-analysis-shows-cholesterol-lowering-medications-do-not-increase-the-risk-of-lou-gehrigs-disease http://pharmalicensing.com/redirs/news_rss//public/news/view/443591/6/fda-analysis-shows-cholesterol-lowering-medications-do-not-increase-the-risk-of-lou-gehrigs-disease